Nanovibronix Stock Performance
| NAOV Stock | USD 7.16 0.18 2.45% |
NanoVibronix holds a performance score of 7 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.34, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning NanoVibronix are expected to decrease at a much lower rate. During the bear market, NanoVibronix is likely to outperform the market. Use NanoVibronix value at risk, as well as the relationship between the kurtosis and market facilitation index , to analyze future returns on NanoVibronix.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in NanoVibronix are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, NanoVibronix showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.45) | Five Day Return 2.29 | Year To Date Return 4.99 | Ten Year Return (99.07) | All Time Return (99.07) |
Last Split Factor 1:11 | Last Split Date 2025-03-14 |
1 | NanoVibronix stock touches 52-week low at 0.44 amid market challenges - Investing.com | 01/23/2025 |
2 | Acquisition by Goldstein Martin M of 60000 shares of NanoVibronix at 0.84 subject to Rule 16b-3 | 02/07/2025 |
3 | NanoVibronix acquires enteral tech firm ENvue Medical - Investing.com | 02/14/2025 |
4 | Disposition of 563 shares by Brown Stephen Russell of NanoVibronix at 8.84 subject to Rule 16b-3 | 02/24/2025 |
5 | NanoVibronix, Inc. Short Interest Update | 03/13/2025 |
6 | Why Nanovibronix Inc. Surged On Thursday | 03/21/2025 |
7 | UroShield by NanoVibronix Shown to Reduce Healthcare Costs and Improve Patient Care | 04/08/2025 |
8 | NanoVibronix Secures Nasdaq Listing Compliance NAOV Stock News | 04/11/2025 |
9 | 12 Health Care Stocks Moving In Mondays After-Market Session - Benzinga | 04/14/2025 |
| Begin Period Cash Flow | 3.3 M |
NanoVibronix | Build AI portfolio with NanoVibronix Stock |
NanoVibronix Relative Risk vs. Return Landscape
If you would invest 549.00 in NanoVibronix on January 20, 2025 and sell it today you would earn a total of 167.00 from holding NanoVibronix or generate 30.42% return on investment over 90 days. NanoVibronix is currently generating 2.1058% in daily expected returns and assumes 22.8308% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than NanoVibronix, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NanoVibronix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NanoVibronix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NanoVibronix, and traders can use it to determine the average amount a NanoVibronix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0922
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | NAOV | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 22.83 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.11 actual daily | 42 58% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average NanoVibronix is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NanoVibronix by adding it to a well-diversified portfolio.
NanoVibronix Fundamentals Growth
NanoVibronix Stock prices reflect investors' perceptions of the future prospects and financial health of NanoVibronix, and NanoVibronix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NanoVibronix Stock performance.
| Return On Equity | -1.61 | ||||
| Return On Asset | -0.43 | ||||
| Profit Margin | (1.45) % | ||||
| Operating Margin | (3.09) % | ||||
| Current Valuation | 4.8 M | ||||
| Shares Outstanding | 759.3 K | ||||
| Price To Earning | (5.34) X | ||||
| Price To Book | 8.67 X | ||||
| Price To Sales | 2.13 X | ||||
| Revenue | 2.56 M | ||||
| Gross Profit | 1.51 M | ||||
| EBITDA | (3.55 M) | ||||
| Net Income | (3.71 M) | ||||
| Cash And Equivalents | 3.94 M | ||||
| Cash Per Share | 0.14 X | ||||
| Total Debt | 116 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 3.07 X | ||||
| Book Value Per Share | 1.66 X | ||||
| Cash Flow From Operations | (2.52 M) | ||||
| Earnings Per Share | (151.03) X | ||||
| Market Capitalization | 5.44 M | ||||
| Total Asset | 3.63 M | ||||
| Retained Earnings | (69.8 M) | ||||
| Working Capital | 609 K | ||||
| Current Asset | 1.78 M | ||||
| Current Liabilities | 297 K | ||||
About NanoVibronix Performance
Evaluating NanoVibronix's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NanoVibronix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NanoVibronix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 761.63 | 799.72 | |
| Return On Tangible Assets | (1.02) | (1.07) | |
| Return On Capital Employed | (3.95) | (3.75) | |
| Return On Assets | (1.02) | (1.07) | |
| Return On Equity | (5.91) | (5.61) |
Things to note about NanoVibronix performance evaluation
Checking the ongoing alerts about NanoVibronix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NanoVibronix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NanoVibronix is way too risky over 90 days horizon | |
| NanoVibronix appears to be risky and price may revert if volatility continues | |
| NanoVibronix has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.56 M. Net Loss for the year was (3.71 M) with profit before overhead, payroll, taxes, and interest of 1.51 M. | |
| NanoVibronix currently holds about 3.94 M in cash with (2.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14. | |
| NanoVibronix has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: 12 Health Care Stocks Moving In Mondays After-Market Session - Benzinga |
- Analyzing NanoVibronix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NanoVibronix's stock is overvalued or undervalued compared to its peers.
- Examining NanoVibronix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NanoVibronix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NanoVibronix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NanoVibronix's stock. These opinions can provide insight into NanoVibronix's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NanoVibronix Stock Analysis
When running NanoVibronix's price analysis, check to measure NanoVibronix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoVibronix is operating at the current time. Most of NanoVibronix's value examination focuses on studying past and present price action to predict the probability of NanoVibronix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoVibronix's price. Additionally, you may evaluate how the addition of NanoVibronix to your portfolios can decrease your overall portfolio volatility.